Nightstar Therapeutics plc Company Profile

00:55 EDT 16th June 2019 | BioPortfolio

Nightstar is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases including choroideremia, X-linked retinitis pigmentosa and Best vitelliform macular dystrophy.

News Articles [922 Associated News Articles listed on BioPortfolio]

Biogen closes $800m Nightstar Therapeutics acquisition

Biogen has closed an acquisition of Nightstar Therapeutics for around $800m, marking its entry into the ophthalmology medicines market. Nightstar...Read More... The post Biogen closes $800m Nightstar ...

Biogen Takes Nightstar Therapeutics for $877 Million

Biogen has agreed to acquire Nightstar Therapeutics, a clinical-stage gene therapy company based in London, UK. The US drug firm will pay Nightstar shareholders $25.50 for each share they hold, valuin...

Biogen to acquire UK-based Nightstar Therapeutics for $877m

Based in London, Nightstar is engaged in the development and commercialization of one-time treatments for patients with inherited retinal diseases. The company is mainly focused on the development Th...

Syncona’s Nightstar Therapeutics to be bought by Biogen for $877 million

Nightstar Therapeutics has agreed to be acquired by Biogen.

Biogen to buy gene therapy firm Nightstar Therapeutics for $800m

US-based biotechnology company Biogen has signed an agreement to acquire UK-based gene therapy firm Nightstar Therapeutics for a cash consideration...Read More... The post Biogen to buy gene therapy f...

Nightstar to start Phase II/III trial of NSR-RPGR for XLRP

Nightstar Therapeutics will begin a Phase II/III trial to investigate the safety and efficacy of NSR-RPGR for the treatment of...Read More... The post Nightstar to start Phase II/III trial of NSR-RPGR...

After AGTC Deal Flops, Biogen Bets $800M on Gene Therapy Rival Nightstar

Biogen’s biggest recent foray into gene therapy, an ill-fated pact with AGTC, didn’t pay dividends. So the company this morning agreed to buy a rival, Nightstar Therapeutics, and its portfolio of ...

Biogen Inc.: Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million

Nightstar acquisition further bolsters Biogen's pipeline with the addition of two mid- to late-stage clinical assets as well as preclinical programsCAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) ...

Drugs and Medications [27 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [kastle therapeutics, llc]


Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [breathe easy therapeutics, inc]


Diclofenac sodium delayed release [cambridge therapeutics technologies, llc]

Diclofenac Sodium

Olopatadine hydrochloride [a-s medication solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [477 Associated PubMed Articles listed on BioPortfolio]

The use of fast photochemical oxidation of proteins coupled with mass spectrometry in protein therapeutics discovery and development.

Structural analysis of protein therapeutics is a challenging task owing to complexities associated with large molecular size and 3D structures. Recent advances in fast photochemical oxidation of prote...

Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.

There is mounting evidence supporting the use of biologic therapeutics for the management of noninfectious uveitis (NIU). This review highlights: biologics with documented efficacy in NIU; agents with...

CRISPR: a promising tool for lipid physiology and therapeutics.

The purpose is to review recent progress in applying the CRISPR/Cas9 system to lipid metabolism and therapeutics.

Bacterial magnetosomes-based nanocarriers for co-delivery of cancer therapeutics in vitro.

In recent times, co-delivery of therapeutics has emerged as a promising strategy for treating dreadful diseases such as cancer.

Advancing Nucleic Acid Therapeutics by Setting Uniform Standards for Experimental Controls.

Clinical Trials [179 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1340 Associated Companies listed on BioPortfolio]

Nightstar Therapeutics Limited

Nightstar is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal d...

Nightstar Therapeutics plc

Nightstar is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal d...

NightstaRx Limited

Nightstar is a leading retinal gene therapy company focused on developing and commercializing novel, potentially curative one-time treatments for patients suffering from rare inhe...

NightstaRx Ltd

Nightstar is a private biopharmaceutical company, spun-out from the University of Oxford in 2014, focused on the development of therapies for retinal dystrophies. The Company is f...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

More Information about "Nightstar Therapeutics plc" on BioPortfolio

We have published hundreds of Nightstar Therapeutics plc news stories on BioPortfolio along with dozens of Nightstar Therapeutics plc Clinical Trials and PubMed Articles about Nightstar Therapeutics plc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Nightstar Therapeutics plc Companies in our database. You can also find out about relevant Nightstar Therapeutics plc Drugs and Medications on this site too.

Quick Search


Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Muscular Dystrophy
Muscular dystrophy is a group of degenerative inherited disorders causing muscle weakness and loss of muscle tissue. The different types are Becker muscular dystrophy, Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral mu...

Corporate Database Quicklinks

Searches Linking to this Company Record